Future of Cell Therapy in the Regenerative Medicine Market

Friday, July 8, 2016 Genetics & Stem Cells News J E 4

LONDON, July 7, 2016 /PRNewswire/ -- Future of Cell Therapy in the Regenerative Medicine Market : Combination Therapies and Advanced Manufacturing Techniques are the New Criteria Shaping the $4 Billion MarketThis Frost & Sullivan research service analyses the current trends, forecasts and the external factors influencing the global cell therapy market. It also studies top participants in the market, disruptive pipeline products, and the opportunities in combination therapy. In addition, it provides a detailed commercialization analysis of research and development (R&D), manufacturing, and funding considerations.Key Takeaways—How is this Market Important to You?Cell therapy is a fast-growing, emerging market. Stem cell therapy, comprising the largest part of the market, has the largest number of clinical trials globally. Furthermore, combination therapies, such as stem cell-gene and cell-gene, are showing great curative potential, which has led to US Food and Drug Administration (FDA) fast-track status.Significant opportunities exist for small- to medium-sized companies in this rapidly expanding market. With growing government and private funds, the global market is ripe for new companies with innovative therapies to come to the forefront.Large pharmaceutical companies such as Pfizer, Novartis, and Juno Therapeutics are entering the market because there is strong evidence of the safety and efficacy of numerous products in the pipeline. In addition, the curative potential of some of the cell-gene therapies is driving the creation of new partnerships, mergers, and acquisitions.As the commercial production of stem cell, cell, and gene therapies increases, the need for fully-enclosed systems, such as bioreactors, and disposable products for Current Good Manufacturing Practice (CGMP) production will also grow.Very few large-scale manufacturing facilities exist. The cost of goods sold is high relative to marketable product output. Vector production capabilities are currently limiting the rate of production for stem cell-gene and cell-gene products.Key Questions this Study will Answer- Will the cell therapy market disrupt your current business or create growth opportunities? What do you need to know?- What are some of the key products and companies changing the dynamics of this market?- Where are the hottest segments in this market? Where is the most interest in terms of funding and innovation?- What are some of the most disruptive products by disease indication in this space?- What are the gaps in the market that encourage penetration and provide opportunities to new entrants?- How are countries refocusing funds and regulations to support this new market? Which countries are at the forefront of this change?Download the full report: ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information: Sarah Smith Research Advisor at Email:  Tel: +44 208 816 85 48 Website:

To view the original version on PR Newswire, visit:

SOURCE ReportBuyer



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Sensors and Intelligent End-point Devices in IoT: ...
India Hyperlocal Market Outlook to 2020 - Driven b...